YMI marketing campaign update and Annual General and Special Meeting Results
Calgary, Alberta – December 6, 2022
For Immediate Release – nDatalyze Corp. (“NDAT” or the “Corporation”) (CSE:NDAT)(OTCQB:NDATF) is pleased to announce that its marketing contractor, BelieveCo (formerly VenturePlay), has provided a full update on the first of three phases for the YMI marketing campaign (the “Campaign”). As expected, Phase One data revealed some indicated user experience (“UX”) changes, that have been incorporated over the past few weeks. Phase One generated a small amount of revenue, which is expected to grow during Phase Two. Phase Two has now begun and includes a Canada-wide release (Phase One was Alberta-only), enhanced user tracking, influencer contracts, social media boosts, and increased digital advertising spend. All three phases are expected to be completed prior to the Corporation’s fiscal year end of February 28, 2023 and all are fully funded by the Corporation’s existing cash balance. A video interview with Dr. Keith Courtney, a Board-Certified Psychiatrist who consulted on YMI’s scoring algorithms, is available here. or at https://youtu.be/trNWPSPYQ5E
YMI is available now at https://ymihealth.ca/
The Corporation further reports that all matters subject to shareholder voting at the Corporation’s Annual and Special Meeting held on November 30, 2022 were passed. Included is the shareholder approval to wind-down or otherwise dispose of the extractor operations, which is believed necessary to clarify the Corporation’s future direction with the investment community and to address negative connotations associated with perceived drug-related operations. An additional factor is that the extractor operations have become marginally economic due to factors beyond the Corporation’s control, which factors the Corporation believes will continue for the foreseeable future.
About nDatalyze Corp.:
nDatalyze Corp. generates technology-based, health-related solutions. The YMI division is developing a machine-learning based, online consumer mental health application with it’s database licensing division focusing on providing a specialized health-related Reference Database to application developers and researchers. YMI is based on the Corporation’s proprietary Reference Database consisting of >1200 biometric records complete with associated electroencephalogram (“EEG”) data. With installations worldwide, it’s Medxtractor division manufactures small-scale bio-extractors that are used to extract compounds from a variety of botanical biomasses. While the Medxtractor division is currently generating cash flow, YMI is in development and accordingly the Corporation cannot accurately predict if or when this application will become a cash flow generator.
FOR FURTHER INFORMATION, PLEASE CONTACT:
James Durward, President and CEO
Telephone: (403) 689-3901
Email: [email protected]
RBMG – RB Milestone Group LLC
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
The information in this news release includes certain information and statements about management’s view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward looking statements. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Corporation believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.